HPV testing for primary cervical screening: Laboratory issues and evolving requirements for robust quality assurance

Journal of Clinical Virology

Volumn 76, Issue , 2016, Pages S22-S28

  Carozzi, Francesca Maria ^a   Del Mistro, Annarosa ^b   Cuschieri, Kate ^c   Frayle, Helena ^b   Sani, Cristina ^a   Burroni, Elena ^a  

^a CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Cervical cancer screening; HPV DNA testing; HPV EQA; HPV IQA; Quality assurance

Indexed keywords

CANCER SCREENING; DIAGNOSTIC ACCURACY; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; LABORATORY TEST; MOLECULAR DIAGNOSTICS; NONHUMAN; PAPANICOLAOU TEST; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; TRANSPORT MEDIUM; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VAGINA SMEAR KIT; WART VIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CLASSIFICATION; COMPLICATION; DIAGNOSTIC KIT; EARLY CANCER DIAGNOSIS; FEMALE; GENETICS; GENOTYPING TECHNIQUE; INTERNATIONAL COOPERATION; ISOLATION AND PURIFICATION; LABORATORY; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVENTIVE HEALTH SERVICE; PROCEDURES; STANDARDS; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

DIAGNOSTIC KIT;

CERVICAL INTRAEPITHELIAL NEOPLASIA; DIAGNOSTIC SERVICES; EARLY DETECTION OF CANCER; FEMALE; GENOTYPING TECHNIQUES; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; INTERNATIONAL COOPERATION; LABORATORIES; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; QUALITY CONTROL; REAGENT KITS, DIAGNOSTIC; UTERINE CERVICAL NEOPLASMS;

EID: 84960446102     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2015.10.025     Document Type: Review

References (22)

1. Naucler P., Ryd W., Törnberg S., Strand A., Wadell G., Elfgren K., Rådberg T., Strander B., Johansson B., Forslund O., Hansson B.G., Rylander E., Dillner J. Human papillomavirus and papanicolaou tests to screen for cervical cancer. N. Engl. J. Med. 2007, 357:1589-1597. Erratum in: N. Engl. J. Med. (2008);359:1637. Johansson, Bo [added].
2. Kitchener H.C., Almonte M., Gilham C., Dowie R., Stoykova B., Sargent A., Roberts C., Desai M., Peto J. ARTISTIC Trial Study Group. ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol. Assess. 2009, 13(iii-iv):1-150. 10.3310/hta13510.
3. Ronco G., Giorgi-Rossi P., Carozzi F., Confortini M., Dalla Palma P., Del Mistro A., Ghiringhello B., Girlando S., Gillio-Tos A., De Marco L., Naldoni C., Pierotti P., Rizzolo R., Schincaglia P., Zorzi M., Zappa M., Segnan N., Cuzick J. New Technologies for Cervical Cancer screening (NTCC) Working Group. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010, 57:70360-70362. 10.1016/S1470-2045(09).
4. Rijkaart D.C., Berkhof J., Rozendaal L., van Kemenade F.J., Bulkmans N.W., Heideman D.A., Kenter G.G., Cuzick J., Snijders P.J., Meijer C.J. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 2012, 88:0-70296. 10.1016/S1470-2045(11).
5. Ronco G., Dillner J., Elfstrom K.M., Tunesi S., Snijders P.J., Arbyn M., Kitchener H., Segnan N., Gilham C., Giorgi-Rossi P., Berkhof J., Peto J., Meijer C.J. International HPV, screening working group. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014, 383:524-532.
6. Meijer C.J., Berkhof J., Castle P.E., Hesselink A.T., Franco E.L., Ronco G., Arbyn M., Bosch F.X., Cuzick J., Dillner J., Heideman D.A., Snijders P.J. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int. J. Cancer 2009, 124:516-520.
7. Poljak M., Cuzick J., Kocjan B.J., Iftner T., Dillner J., Arbyn M. Nucleic acid tests for the detection of Alpha Human Papillomaviruses. Vaccine 2012, 30S:F100-F106.
8. Arbyn M., Snijders P.J., Meijer C.J., Berkhof K., Cuschieri B.J., Poljak M. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?. Clin. Microbiol. Infect. 2015, 21:817-826.
9. Ronco G., Giorgi-Rossi P., Giubilato P., Del Mistro A., Zappa M., Carozzi F. HPV screening survey working group. A first survey of HPV-based screening in routine cervical cancer screening in Italy. Evidemiol. Prev. 2015, 3.
10. HPV primary screening in the NHS Cervical Screening Programme (last accessed on 18.08.15). http://www.cancerscreening.nhs.uk/cervical/hpv-primary-screening.html.
11. Health Council of the Netherlands. Population screening for cervical cancer. The Hague: Health Council of the Netherlands, 2011; publication no. 2011/07E.
12. Epidemiologia & Prevenzione 2012, 36 (3-4), suppl. 1.
13. Bouvard R., Baan K., Straif Y., Grosse B., El Ghissassi F., Benbrahim-Tallaa N., Guha C., Galichet L., Cogliano V. WHO International Agency for Research on Cancer Monograph Working Group. A review of human carcinogens-part B: biological agents. Lancet Oncol. 2009, 10(4):321-322.
14. von Karsa L., Arbyn De Vuyst M.H., Dillner J., Dillner L., Franceschi S., Patnick J., Ronco G., Segnan N., Suonio E., Törnberg S., Anttila A. European guidelines for qulity assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavirus Res. 2015, 1:22-31.
15. International Organization for Standardization (ISO)15189:2007 Medical laboratories-Particular requirements for quality and competence. Geneva: ISO, 2007.
16. Eklund C., Forslund O., Wallin K.-L., Dillner J. Global improvement in genotyping of human papillomavirus DNA: the 2011HPV LabNet International Proficiency Study. J. Clin. Microbiol. 2014, 52:449-459.
17. Arbyn M., Anttila A., Jordan J., Ronco G., Schenck U., Segnan N., Wiener H., Herbert A., von Karsa L. European guidelines for quality assurance in cervical cancer screening. Second edition-summary document. Ann. Oncol. 2010, 21:448-458.
18. Dubbink H.J., Deans Z.C., Tops B.B., van Kemenade F.J., Koljenović S., van Krieken H.J., Blokx W.A., Dinjens W.N., Groenen P.J. Next generation diagnostic molecular pathology: critical appraisal of quality assurance in Europe. Mol. Oncol. 2014, 8:830-839.
19. Van Krieken J.H., Siebers A.G., Normanno N., the Q., uality A., for M., olecular P. European Consensus Conference for external quality assessment in molecular pathology. Ann. Oncol. 2013, 24:1958-1963.
20. Schijver I., Aziz N., Jennings L.J., Richards C.S., Voelkerding K.V., Weck K.E. Methods-based proficiency testing in molecular genetic pathology. J. Mol. Diagn. 2014, 16:283-287.
21. Carozzi F., De Marco L., Gillio-Tos A., Del Mistro A., Girlando S., Baboci L., Trevisan M., Burroni E., Grasso S., Giorgi Rossi P., Ronco G. NTCC Working group.Age and geographic variability of human papillomavirus high-risk genotype distribution in a large unvaccinated population and of vaccination impact on HPV prevalence. J. Clin. Virol. 2014, 60:257-263. Epub 2014 Apr 18. 10.1016/j.jcv.2014.04.009.
22. Baussano I., Elfström K.M., Lazzarato F., Gillio-Tos A., De Marco L., Carozzi F., Del Mistro A., Dillner J., Franceschi S., Ronco G. Type-specific human papillomavirus biological features: validated model-based estimates. PLoS One 2013, 8:e81171. eCollection 2013. 10.1371/journal.pone.0081171.